Cargando…
SAMHD1 protects cancer cells from various nucleoside-based antimetabolites
Recently, we demonstrated that sterile α motif and HD domain containing protein 1 (SAMHD1) is a major barrier in acute myelogenous leukemia (AML) cells to the cytotoxicity of cytarabine (ara-C), the most important drug in AML treatment. Ara-C is intracellularly converted by the canonical dNTP synthe...
Autores principales: | Herold, Nikolas, Rudd, Sean G., Sanjiv, Kumar, Kutzner, Juliane, Bladh, Julia, Paulin, Cynthia B. J., Helleday, Thomas, Henter, Jan-Inge, Schaller, Torsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499833/ https://www.ncbi.nlm.nih.gov/pubmed/28436707 http://dx.doi.org/10.1080/15384101.2017.1314407 |
Ejemplares similares
-
SAMHD1 is a barrier to antimetabolite-based cancer therapies
por: Rudd, Sean G., et al.
Publicado: (2017) -
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy
por: Rudd, Sean G, et al.
Publicado: (2020) -
Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
por: Tsesmetzis, Nikolaos, et al.
Publicado: (2018) -
Nucleoside salvage and resistance to antimetabolite anticancer agents.
por: Fox, M., et al.
Publicado: (1991) -
Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection
por: Lee, He-Jin, et al.
Publicado: (2010)